All In Biotech

Drug Trial Radar · NCT01457417

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

A Two Part Phase 1 Multicenter Open-label Study of DKN-01 Given Intravenously. Part A: Dose-Escalation in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: Expansion Cohort in Patients With Relapsed / Refractory Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Sep 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Jan 2012

Primary completion

Dec 2013

Study completion Dec 2013

Sponsor

Lead sponsor
Leap Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 24, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer. To characterize the pharmacokinetic parameters of DKN-01 in cancer patients who are intolerant to standard/approved therapies.

Conditions

  • Multiple Myeloma
  • Solid Tumors
  • Non-Small Cell Lung Cancer

Interventions

  • DKN-01Drug

    DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summary of Total Adverse Events (AE)Time frame: Baseline to study completion (approximately 3 months)
  2. Summary of Patients With Adverse Events (AE)Time frame: Baseline to study completion (approximately 3 months)
  3. Progression Free Survival (PFS) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC)Time frame: Time from the date of signed informed consent to the first date of objectively determined progressive disease or death from any cause

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Scottsdale Healthcare

    Scottsdale, Arizona

  • New York Oncology Hematology, P.C.

    Albany, New York

  • Greenville Hospital System University Medical Center

    Greenville, South Carolina

  • Texas Oncology - Baylor, Charles A. Sammonds Cancer Center

    Dallas, Texas

  • Texas Oncology - Tyler

    Tyler, Texas

  • Virginia Oncology Associated

    Norfolk, Virginia

  • Virginia Commonwealth University - Massey Cancer Center

    Richmond, Virginia

  • Northwest Cancer Specialists, P.C.

    Vancouver, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.